📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
35 announcements match the current filters (relevance ≥ 5).
Gland Pharma Q4 FY26 Results: Adjusted PAT Surges 97% YoY to ₹3,667 Million
Gland Pharma reported a robust performance for Q4 FY26, with consolidated revenue growing 22% YoY to ₹17,428 million. The company's Adjusted PAT saw a significant jump of 97% YoY, reaching ₹3,667 million, driven by improved operational efficiencies and a 153% increase in other income. For the full year FY26, revenue increased by 14% to ₹64,307 million, while Adjusted PAT grew by 50% to ₹10,455 million. The base business (Gland) also showed strong momentum with a 22% YoY revenue growth and a 45% increase in Adjusted PAT for the quarter.
Key Highlights
Consolidated Revenue for Q4 FY26 grew 22% YoY to ₹17,428 million.
Adjusted PAT for Q4 FY26 nearly doubled, rising 97% YoY to ₹3,667 million.
Adjusted EBITDA margin improved significantly to 30% in Q4 FY26 from 24% in Q4 FY25.
Full-year FY26 Revenue stood at ₹64,307 million, up 14% compared to FY25.
Base business (Gland) maintained a healthy Gross Profit margin of 62% in Q4 FY26.
👀 What to Watch
The strong growth in margins and PAT suggests a recovery in the core business and improved operational leverage. Investors should maintain a positive outlook while monitoring the sustainability of these margins and the progress of the R&D pipeline.
Gland Pharma Q4 FY26: Adj. PAT Surges 97% YoY to ₹3,667 Mn; ₹20 Dividend Declared
Gland Pharma reported a robust Q4 FY26 with consolidated revenue growing 22% YoY to ₹17,428 million, driven by strong performance in the US and Europe markets. Adjusted PAT saw a significant jump of 97% YoY to ₹3,667 million, while adjusted EBITDA margins expanded to 30% from 24% in the previous year. The CDMO segment remains a key growth driver, contributing 46% of total revenue with a 36% YoY growth rate. The board has also recommended a final dividend of ₹20 per share, reflecting strong cash flow and profitability.
Key Highlights
Consolidated Q4 revenue grew 22% YoY to ₹17,428 million, with the US market growing 24% YoY.
Adjusted PAT for Q4 FY26 surged 97% YoY to ₹3,667 million, while full-year FY26 PAT grew 50% to ₹10,455 million.
Adjusted EBITDA margin improved significantly to 30% in Q4 FY26 compared to 24% in Q4 FY25.
CDMO business showed strong momentum, contributing 46% of total revenue and growing 36% YoY in Q4.
The company launched 31 products in the USA during FY26 and filed 24 ANDAs during the year.
👀 What to Watch
Investors should view these results positively as the company demonstrates strong margin recovery and robust growth in its core US market and CDMO segment. The healthy pipeline of complex injectables and the recommended ₹20 dividend provide a positive outlook for long-term shareholders.
Gland Pharma Recommends ₹20 Final Dividend; Approves Audited FY26 Financial Results
Gland Pharma has reported its audited financial results for the fiscal year ended March 31, 2026, receiving an unmodified audit opinion from Deloitte Haskins & Sells. The Board has recommended a substantial final dividend of ₹20 per equity share (2000% of face value) for the financial year 2025-26. The record date for dividend eligibility is set for August 11, 2026, with the Annual General Meeting scheduled for August 25, 2026. The consolidated results incorporate the performance of international subsidiaries, including the Cenexi Group in Europe.
Key Highlights
Recommended a final dividend of ₹20 per equity share (2000% of face value of ₹1) for FY 2025-26.
Statutory auditors issued an unmodified opinion on both standalone and consolidated financial statements.
Record date for determining dividend eligibility is fixed as Tuesday, August 11, 2026.
The 48th Annual General Meeting (AGM) is scheduled to be held on August 25, 2026.
Consolidated results include performance from key subsidiaries like Cenexi (France) and Gland Pharma USA.
👀 What to Watch
Investors should monitor the upcoming investor presentation for detailed growth metrics in the US and European markets and note the ex-dividend date occurring around mid-August.
Gland Pharma Reappoints Ms. Naina Lal Kidwai as Independent Director for 5-Year Term
Gland Pharma has received shareholder approval to reappoint Ms. Naina Lal Kidwai as an Independent Director for a second five-year term, effective from May 17, 2026, to May 16, 2031. Ms. Kidwai is a highly distinguished professional, currently serving as Chairman of Rothschild & Co India and having previously chaired HSBC India. The reappointment, conducted via postal ballot, also includes approval for remuneration via commission on profits. This move ensures continuity in the company's high-level governance and strategic oversight by a veteran of the Indian financial and corporate sector.
Key Highlights
Reappointed for a second consecutive term of 5 years starting May 17, 2026, until May 16, 2031.
Shareholders approved the reappointment and payment of commission on profits through a postal ballot.
Ms. Kidwai brings extensive experience as the former Chairman of HSBC India and current Chairman of Rothschild & Co India.
She is a recipient of the Padma Shri and holds an MBA from Harvard Business School, serving on multiple global boards like Holcim and Biocon.
👀 What to Watch
Investors should view this as a positive development for corporate governance, as it retains a highly respected and experienced independent voice on the board. No immediate portfolio action is required based on this announcement.
Gland Pharma Shareholders Approve Naina Lal Kidwai's Reappointment with 94.18% Majority
Gland Pharma Limited has successfully passed a special resolution via postal ballot to reappoint Ms. Naina Lal Kidwai as an Independent Director. The resolution also approved the payment of commission on profits as part of her remuneration package. While the resolution passed with an overall majority of 94.18%, there was notable dissent from public institutional investors, with 13.58% of their votes cast against the proposal. Promoters remained fully supportive, voting 100% in favor of the reappointment.
Key Highlights
Special resolution for the reappointment of Ms. Naina Lal Kidwai as Independent Director passed with 94.18% of total votes.
Total votes polled were 149,437,703, accounting for 90.70% of the total outstanding shares.
Public institutional investors cast 8,694,537 votes (13.58%) against the resolution.
Promoter group provided full support with 85,393,894 votes cast 100% in favor.
The approval includes a provision for remuneration via commission on company profits.
👀 What to Watch
This is a routine governance matter ensuring board continuity; no immediate action is required. Investors should note the moderate institutional dissent regarding the remuneration structure but recognize that the board's leadership remains stable.
Gland Pharma Re-appoints Naina Lal Kidwai as Independent Director for 5-Year Term
Gland Pharma's Board has approved the re-appointment of Ms. Naina Lal Kidwai as an Independent Director for a second five-year term. This term will commence on May 17, 2026, and extend until May 16, 2031, subject to shareholder approval via postal ballot. Ms. Kidwai is a highly distinguished professional, currently serving as Chairman of Rothschild & Co India and holding a Padma Shri award. Her continued presence on the board is expected to provide strong corporate governance and strategic oversight for the company.
Key Highlights
Re-appointment of Ms. Naina Lal Kidwai for a second term of 5 consecutive years.
New term effective from May 17, 2026, through May 16, 2031.
Shareholder approval to be sought via postal ballot and e-voting as per SEBI regulations.
Ms. Kidwai brings extensive experience as former Chairman of HSBC India and current Chairman of Rothschild & Co India.
👀 What to Watch
No immediate action is required as this is a routine governance matter. The retention of a high-profile independent director like Ms. Kidwai is a positive signal for long-term corporate governance and board stability.
Gland Pharma Receives USFDA Tentative Approval for Brimonidine Tartrate Ophthalmic Solution
Gland Pharma has received tentative approval from the USFDA for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC), a generic version of Bausch & Lomb's Lumify. The product is indicated for the relief of eye redness and targets a US market segment valued at approximately USD 39 million for the twelve months ending September 2025. While the approval is tentative, it marks a significant step in expanding Gland's ophthalmic portfolio in the US market. The company will now await final approval to commence commercial production and distribution under its B2B model.
Key Highlights
Received USFDA tentative approval for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC).
Product is bioequivalent to the reference drug Lumify, owned by Bausch & Lomb Inc.
Target market size in the US is approximately USD 39 million as per IQVIA data for the year ending Sept 2025.
The product is indicated for the relief of eye redness, strengthening Gland's ophthalmic segment.
Approval aligns with Gland's strategy to expand its sterile injectable and ophthalmic footprint globally.
👀 What to Watch
Investors should view this as a positive development for Gland's R&D pipeline, though they should monitor the timeline for final approval and commercial launch. The relatively small market size of USD 39 million suggests this is an incremental rather than transformative addition to revenue.
Gland Pharma CEO Shyamakant Giri Resigns; Effective April 30, 2026
Gland Pharma Limited has announced the resignation of Mr. Shyamakant Giri from his role as Chief Executive Officer and Key Management Personnel. The resignation was submitted on February 24, 2026, and officially accepted by the Board of Directors on March 3, 2026. Mr. Giri will continue in his role until the close of business hours on April 30, 2026, providing a transition period of nearly two months. The departure is attributed to his decision to pursue new professional opportunities outside the company.
Key Highlights
Mr. Shyamakant Giri to step down as CEO and KMP effective April 30, 2026.
Resignation letter was dated February 24, 2026, and accepted by the Board on March 3, 2026.
The company has a transition window of approximately 8 weeks to manage the leadership change.
The departure is voluntary as the executive seeks to pursue new opportunities.
👀 What to Watch
Investors should monitor the company's upcoming announcements regarding a successor to ensure leadership continuity. While the notice period provides some stability, the appointment of a new CEO will be a critical factor for the stock's future performance.
Gland Pharma Appoints Dr. Jitendra Gangwal as VP of R&D to Lead Complex Product Development
Gland Pharma has appointed Dr. Jitendra Gangwal as Vice-President of Research and Development, effective February 18, 2026. Dr. Gangwal brings over 24 years of experience in pharmaceutical R&D, having previously held leadership roles at Dr. Reddy’s, Glenmark, and Alkem Laboratories. His track record includes the development of 55+ products and filing 10+ patents, specifically in complex delivery systems like liposomes and peptides. This strategic hire is intended to bolster Gland Pharma's pipeline of high-value complex injectables for regulated global markets.
Key Highlights
Dr. Jitendra Gangwal appointed as VP (R&D) with over 24 years of pharmaceutical experience.
Developed 55+ products across injections, ophthalmics, inhalation, and nasal routes.
Filed 10+ patents and led multiple 505(b)(2) and ANDA filings in previous roles.
Expertise in complex parenterals, nano-crystals, liposomes, and advanced polymer-based delivery systems.
👀 What to Watch
Investors should view this as a positive move to strengthen the company's core R&D capabilities. Monitor the pace of new ANDA filings and complex product approvals over the next 12-18 months to gauge the impact of this leadership change.
Gland Pharma Gets USFDA Approval for Zoledronic Acid Injection; US Market Size $6.7 Million
Gland Pharma has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Zoledronic Acid Injection (4 mg/100 mL) in single-dose bags. The product is indicated for treating Hypercalcemia of Malignancy, Multiple Myeloma, and Bone Metastases of Solid Tumors. According to IQVIA data, the product's US market sales were approximately USD 6.7 million for the twelve months ending November 2025. This approval strengthens Gland's sterile injectable portfolio in the key US market.
Key Highlights
Received USFDA approval for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/mL) Single-Dose Bags
Product is bioequivalent and therapeutically equivalent to the reference listed drug by InfoRLife
Target indications include Hypercalcemia of Malignancy and Multiple Myeloma
US market sales for the product were approximately USD 6.7 million for the year ending November 2025
👀 What to Watch
Investors should view this as a positive incremental addition to Gland's US portfolio, though the individual market size is modest. Monitor the company's ability to maintain its track record of USFDA approvals and market share gains in the generic injectables space.
Gland Pharma Q3 FY26 Revenue Up 22% to ₹1,695 Cr; Plans ₹2,000 Cr Capex Over 5 Years
Gland Pharma reported a strong Q3 FY26 with revenue growing 22% YoY to INR 16,954 million and adjusted EBITDA rising 25% to INR 4,490 million. The company announced a significant five-year capex plan of INR 2,000 crores focused on complex injectables, BFS, and ophthalmic lines. A major capacity expansion for cartridge fill and finish from 40 million to 140 million units is underway to target the GLP-1 and peptide markets. Management also noted a visible EBITDA turnaround at Cenexi and maintained a high R&D spend of 5.4% of revenue.
Key Highlights
Revenue grew 22% YoY to INR 16,954 million in Q3 FY26, with 9M FY26 revenue up 12%.
Adjusted EBITDA increased 25% YoY to INR 4,490 million, reflecting better operating leverage.
Announced INR 2,000 crore capex over the next 5 years for brownfield expansions and CDMO contracts.
Expanding cartridge fill and finish capacity by 250% from 40 million to 140 million units.
Filed 9 ANDAs and launched 9 new products in the U.S. market during the quarter.
👀 What to Watch
Investors should monitor the execution of the ₹2,000 Cr capex plan and the ramp-up of the expanded cartridge capacity, which are critical for long-term value growth. The turnaround in Cenexi and strong EBITDA growth suggest improving operational efficiency and a positive outlook for the stock.
Gland Pharma Q3 FY26: Adj. PAT Surges 37% YoY to ₹2,797 Mn; Revenue Up 22%
Gland Pharma delivered a strong performance in Q3 FY26, with consolidated revenue growing 22% YoY to ₹16,954 Mn. The company's Adjusted PAT saw a significant jump of 37% YoY to ₹2,797 Mn, supported by a recovery in margins. Adjusted EBITDA margins improved to 26% from 23% in the previous quarter, reflecting better operational efficiency. The core base business remains the primary driver, contributing ₹11,790 Mn to revenue with a healthy 28% PAT margin.
Key Highlights
Consolidated Revenue from operations grew 22% YoY and 14% QoQ to ₹16,954 Mn
Adjusted PAT increased 37% YoY to ₹2,797 Mn, with a sharp 52% sequential growth
Adjusted EBITDA margin expanded to 26% in Q3 FY26 from 23% in Q2 FY26
Base business revenue grew 16% YoY to ₹11,790 Mn with an Adjusted PAT of ₹3,274 Mn
R&D expenditure for the base business stood at ₹650 Mn, accounting for 5.5% of its revenue
👀 What to Watch
The strong double-digit growth in both top-line and bottom-line suggests a robust recovery in the injectable segment. Investors should maintain a positive outlook given the margin expansion and steady performance of the core business.
Gland Pharma Q3 FY26: Revenue Up 22% YoY, Adj. PAT Surges 37% to ₹2,797 Mn
Gland Pharma reported a robust performance for Q3 FY26, with consolidated revenue growing 22% YoY to ₹16,954 million. The growth was primarily driven by strong execution in the US and Europe, alongside the Cenexi business reaching breakeven. Adjusted PAT witnessed a significant 37% YoY increase to ₹2,797 million, while Adjusted EBITDA margins remained healthy at 26%. Management highlighted consistent execution and a ramp-up in CDMO contracts as key drivers for future momentum.
Key Highlights
Consolidated Revenue from operations increased 22% YoY to ₹16,954 million.
Adjusted PAT grew by 37% YoY to ₹2,797 million, with margins improving to 16%.
European market revenue surged 54% YoY to ₹4,071 million, while US revenue grew 19% to ₹8,685 million.
Adjusted EBITDA stood at ₹4,490 million, up 25% YoY, with a margin of 26%.
R&D investments increased to ₹650 million from ₹437 million in the previous year.
👀 What to Watch
The results indicate a strong recovery in profitability and successful integration of the Cenexi acquisition. Investors may consider this a positive signal for long-term growth, especially with the US and European markets showing double-digit growth.
Gland Pharma Q3 Revenue Jumps 22.5% YoY to ₹16,954 Million; Profitability Improves
Gland Pharma reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 22.5% year-on-year to ₹16,953.63 million. Sequentially, revenue increased by 14% from ₹14,868.75 million in the previous quarter, indicating robust business momentum. Profit before tax for the quarter stood at ₹3,864.74 million, showing resilience despite a rise in employee benefit expenses and material costs. The company also confirmed the reappointment of Grant Thornton Bharat LLP as internal auditors for the upcoming financial year.
Key Highlights
Consolidated revenue from operations rose 22.5% YoY to ₹16,953.63 million in Q3 FY26.
Quarter-on-quarter revenue growth was robust at 14% compared to ₹14,868.75 million in Q2 FY26.
Total income for the nine-month period ended Dec 2025 reached ₹48,927.22 million versus ₹43,611.74 million YoY.
Profit before tax for the quarter was ₹3,864.74 million, maintaining healthy operational margins.
Grant Thornton Bharat LLP reappointed as Internal Auditors for the financial year 2026-27.
👀 What to Watch
The strong double-digit growth in revenue both YoY and QoQ suggests a recovery in core markets and effective scale-up. Investors should maintain a positive outlook while monitoring the impact of rising operational costs on net margins.
Gland Pharma Receives USFDA Approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7% (OTC)
Gland Pharma has received USFDA approval for its ANDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The product is a generic equivalent to Alcon's Pataday Once Daily Relief, 0.7%, used for treating ocular itching from allergic conjunctivitis. This approval marks a significant addition to Gland's ophthalmic portfolio in the United States. The company continues to leverage its B2B model to expand its global footprint across 60 countries.
Key Highlights
Approval received from USFDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC).
Therapeutically equivalent to Alcon Laboratories' Pataday Once Daily Relief, 0.7%.
Targeted at the treatment of ocular itching associated with allergic conjunctivitis.
Strengthens Gland Pharma's position in the high-value US ophthalmic market.
👀 What to Watch
This approval is a positive catalyst for long-term growth in the US market; investors should maintain a positive outlook on the stock. Keep an eye on the launch timeline and potential market share gains in the OTC segment.
